The flavonoids quercetin and kaempferol are major constituents of Ginkgo biloba extract. The ATP-binding cassette efflux transporter, breast cancer resistance protein (Bcrp, Abcg2), is involved in the transport of quercetin and represents a possible mechanism for the low bioavailability of quercetin. Our objective was to investigate whether kaempferol inhibits Bcrp-mediated quercetin efflux and determine whether it is a substrate for BCRP. The intracellular uptake of kaempferol, with and without specific inhibitors, was determined in Bcrp 
Introduction
Flavonoids are biologically active polyphenolic compounds that are widely distributed in the plant kingdom. They are composed of a common phenylchromanone structure (C6 -C3-C6). Variations in the patterns of hydroxylation and substitutions in their heterocyclic ring give rise to seven flavonoid subclasses: flavonols, flavones, flavanones, flavanols, isoflavones, chalcones, and anthocyanidins. Among 8000 different flavonoids identified so far, the flavonols quercetin and kaempferol are the most abundant flavonoids. It has been reported that quercetin and kaempferol account for 70 to 76% and 17 to 24% of mean total flavonol intake, respectively (Hertog et al., 1993; Sampson et al., 2002) . The dominant sources of the flavonols quercetin and kaempferol include black and green teas, apple, strawberry, onion, broccoli, kale, and endive (Somerset and Johannot, 2008) . It is estimated that the average daily consumption of quercetin and kaempferol is approximately 30 mg/day (de Vries et al., 1997) . In addition to their presence in the diet, quercetin and kaempferol are also major constituents of several herbal supplements. For example, both quercetin and kaempferol represent the major active ingredients of Gingko biloba, a top selling herbal product (Kang et al., 2010) . Many in vitro and in vivo laboratory studies have confirmed the findings of epidemiological studies indicating that quercetin and kaempferol may reduce the occurrence of various cancers (Mukhtar et al., 1988; Nguyen et al., 2003) . The pharmacological effects of quercetin and kaempferol have been well documented, and both compounds demonstrate antioxidant, anti-inflammatory, neuroprotective, antianxiety, and cognitive enhancing effects (Morand et al., 1998; Havsteen, 2002; Niering et al., 2005; Cho et al., 2006; Zhang et al., 2008) . Although various beneficial effects have been observed in vitro, whether and to what extent these in vitro activities can be extrapolated to in vivo effects is always a concern because both quercetin and kaempferol have poor bioavailability Barve et al., 2009) . Understanding the mechanism(s) behind their low bioavailability would be valuable to improve the bioavailability of these flavonoids.
The extensive first-pass metabolism, mainly phase II conjugation in the liver and in the intestinal wall, has been considered to be the main reason for the low bioavailability of quercetin and kaempferol (Gugler et al., 1975; Manach and Donovan, 2004; Barve et al., 2009 ). Many ATP-binding cassette transporters, including BCRP, P-glycoprotein (P-gp), and multidrug resistance protein 2 (MRP2), are known to be expressed in a number of normal tissues and have a major impact on drug disposition (Schinkel and Jonker, 2003) . Bcrp was found to be involved in the transport of quercetin: the transport of quercetin across MDCK/Bcrp1 cell monolayers was much more efficient in the B-to-A direction than in the A-to-B direction, with a transport ratio of approximately 160; no directional transport was detected in corresponding parental MDCK cells (Sesink et al., 2005) . Therefore, in addition to first-pass extraction by metabolism, intestinal efflux, mediated by transporters such as Bcrp, may also represent a possible mechanism for the low bioavailability of quercetin. Whether Bcrp also contributes to the poor bioavailability of kaempferol is currently unknown.
Of interest, Zhang et al. (2005) found that kaempferol is a potent BCRP inhibitor that inhibits the efflux of mitoxantrone in BCRPoverexpressing MCF-7/MX100 cells with an IC 50 value of 6.04 M. Because quercetin and kaempferol are both commonly present in various fruits, vegetables, and herbal supplements, we hypothesized that an herb-herb interaction between quercetin and kaempferol may occur through the efflux transporter Bcrp. In the current study, we performed a quercetin bidirectional transport study to investigate the effect of kaempferol on the transport of quercetin in MDCK cells transfected with murine Bcrp1. The structure of kaempferol is very similar to that of quercetin, with only one hydroxyl group absent in the B-ring at position 3Ј (Fig. 1) . Based on the structural similarity of these flavonoids, we hypothesized that kaempferol might also be a Bcrp substrate and may inhibit Bcrp-mediated quercetin efflux. Because the role of Bcrp in the transport of kaempferol has not been elucidated before, here we investigated the directional transport of kaempferol in both MDCK-II/Mock and MDCK-II/Bcrp1 cells. The intracellular uptake of kaempferol in Bcrp-expressing MDCK/Bcrp1 cells, in the presence and absence of a Bcrp inhibitor, was also determined in a cellular uptake study. Moreover, to understand whether other efflux transporters also contribute to the low bioavailability of kaempferol, we investigated the role of two efflux transporters P-gp and MRP2 on the transport of kaempferol in P-gp-overexpressing MCF-7/ADR cells and MDCK/MRP2 cells, respectively. Cell Culture. The polarized Madin-Darby canine kidney cell line (MDCK-II) was used in the quercetin bidirectional transport study, kaempferol uptake study, and kaempferol bidirectional transport study. The MDCK-II and its subclone that was transfected with either murine Bcrp1 or empty vector were kindly provided by Dr. Alfred Schinkel (Netherlands Cancer Institute, Amsterdam, The Netherlands). The MRP2-transfected MDCK/MRP2 cells were obtained from Dr. P. Borst (Netherlands Cancer Institute, Amsterdam, The Netherlands). P-gp-overexpressing MCF-7/ADR cells (National Cancer Institute, Bethesda, MD) were used in the kaempferol uptake study. MCF-7/ Sensitive cells and MCF7/ADR cells were obtained from Dr. Susan E. Bates (National Cancer Institute). Both MDCK cells and MCF-7 cells were grown in a 5% CO 2 atmosphere at 37°C and cultured in culture media (Dulbecco's modified Eagle's medium and RPMI 1640 medium, respectively) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml streptomycin. A solution of 0.25% trypsin-EDTA was used to detach the cells from the 75-cm 2 flasks. Kaempferol Cellular Uptake Studies. The intracellular uptake of kaempferol was examined with or without transporter inhibitor (5 M GF120918) in Bcrp1-overexpressing MDCK/Bcrp1 cells, P-gp-overexpressing MCF-7/ADR cells, and P-gp-negative MCF-7/Sensitive cells.
In brief, cells were seeded into six-well plates at a density of 5 ϫ 10 5 cells/well, and uptake studies were started when the cells reached 80 to 90% confluence. A stock solution of kaempferol was prepared in dimethyl sulfoxide at a concentration of 10 mM. On the day of the experiment, the cells were first washed twice with PBS. The medium containing specific concentrations of kaempferol, with or without transporter inhibitors, was then added to each well. The final dimethyl sulfoxide concentration in the transport buffer was 0.1%. After incubation for 1 h at 37°C, the medium was aspirated, and the cells were washed three times with ice-cold PBS. To lyse the attached cells, 1 ml of 0.5% Triton X-100 was added into each well. The concentration of kaempferol in the cell lysates was analyzed by LC-MS/MS and normalized with cellular protein content. The protein concentration in the cell lysates was determined by the bicinchoninic acid protein assay (Pierce Chemical, Rockford, IL).
To determine the intracellular concentrations of kaempferol in MDCK/ Bcrp1 cells under different initial incubating concentrations, eq. 1 was used:
where A _final , A _passive , and A _efflux are the intracellular amounts of kaempferol normalized by cellular protein content. A _final refers to the net amount present at 1 h, whereas A _passive is the amount of kaempferol present due to passive diffusion and A _efflux is the amount of kaempferol effluxed by Bcrp1. A _efflux was 0 (i.e., A _final ϭ A _passive ) when kaempferol was incubated with a BCRP inhibitor (eq. 3). The affinity of kaempferol binding to Bcrp1 was reflected by its K m , which was calculated as in eq. 2:
where C is the concentration of kaempferol that was added into each well, and E max is the maximal capacity of kaempferol to bind to Bcrp1. 6 cells/ well. The cells were grown for 7 days, and the medium was replaced every day. On the day of the transport study, the experiment was performed in triplicate in HBSS (pH 7.4). The cell monolayers were first washed twice with HBSS for 30 min, and the flavonoid (10 M) was then added to either the apical (1.5 ml) or basolateral chamber (2.5 ml) (donor chamber). The samples (120 l) were then taken from the opposite chamber (the receiver chamber) at 15, 30, and 60 min after the addition of the flavonoid. To keep the volume constant, the receiver side was replenished with the same volume of fresh HBSS after each sampling.
The samples were stored at Ϫ20°C until LC-MS/MS analysis. The apparent permeability coefficient of [ 3 H]mannitol, a paracellular marker, across MDCK cell monolayers was measured to test the integrity of the monolayer.
The apparent permeability coefficients (P app ) of kaempferol across MDCK monolayers in both the A-to-B and B-to-A directions were calculated as in eq. 4:
where ⌬Q/⌬t is the rate of kaempferol appearing in the receiver chamber, which is obtained from the slope of the regression line for the transport-time profile of kaempferol across the cell monolayers, C 0 is the initial concentration of kaempferol loaded in the donor chamber, and A is the cell monolayer surface area (4.71 cm 2 ). Sample Preparation and LC-MS/MS Analysis. The concentrations of flavonoids in cells or in transport media were determined by LC-MS/MS. A 100-l aliquot of quercetin or kaempferol samples in cell lysates or transport buffer was deproteinized using an equal volume of methanol. After vortexing, the mixture was centrifuged at 14,000 rpm for 10 min. Then 100 l of the supernatant was transferred into a 200-l vial insert for LC-MS/MS analysis.
LC-MS/MS was performed using a PE SCIEX API 3000 triple-quadruple tandem mass spectrometer (Applied Biosystems, Foster City, CA) linked to a TurboIonSpray interface and a Shimadzu LC10 liquid chromatograph. Analyst 1.4.2 software was used for data acquisition and processing. An XTerra MS C18 column (2.1 ϫ 150 mm i.d., 3.5 m; Waters, Milford, MA) was used, and the flavonols quercetin and kaempferol were eluted with a mobile phase of acetonitrile-water containing 0.1% formic acid (50:50, v/v) at a flow rate of 200 l/min. The retention times of quercetin and kaempferol were 3.1 and 4.8 min, respectively. To minimize the ion suppression caused by the high concentration of salts present in the transport buffer (HBSS), the flow from the LC column was diverted to waste for the first 2 min using an API 2000 diverter valve to prevent the early eluting salts from entering the LC-MS interface. Conditions for MS analysis of quercetin and kaempferol included an ion spray voltage of Ϫ4500 V, a nebulizing pressure of 33 psi, and a temperature of 350°C. Nebulizer and curtain gas flow were 10 and 8 ml/min, respectively. The fragment was induced with collision energy of Ϫ30 eV. The optimized declustering potential, focusing potential, and collision cell exit potential were Ϫ60, Ϫ175 and Ϫ30 V, respectively. The MS was performed in a negative ion mode under multiple reaction monitoring. The m/z ratios of parent ion and product ion of quercetin were 301.1 and 151.1, respectively. The m/z ratios of molecular ion and product ion of kaempferol were 285.2 and 285.2, respectively. The lower limit of quantification of quercetin or kaempferol was 1 ng/ml. The calibration curve was linear over the concentration range of 1 to 500 ng/ml for both compounds.
Statistical Analysis. All analyses were performed using SPSS (SPSS 11.0; SPSS, Inc., Chicago, IL). The differences between the mean values were analyzed for significance using a Student's t test or one-way analysis of variance, followed by Dunnett's test. Differences were considered statistically significant when p Ͻ 0.05.
Results

Quercetin Transport by Bcrp and Inhibition by Kaempferol.
To investigate whether there is a Bcrp-mediated kaempferol-quercetin interaction, we examine the effect of kaempferol in Bcrp-mediated quercetin efflux in a quercetin bidirectional transport study. The mass spectra (Q1 and Q3 scan) of quercetin are shown in Fig. 2, A and B. As shown in Table 1 , the P app, B-A (21.9 Ϯ 4.4 ϫ 10 Ϫ6 cm/s) of quercetin was much higher than the P app, A-B (0.232 Ϯ 0.078 ϫ 10 Ϫ6 cm/s) in MDCK/Bcrp1 cells, whereas this phenomenon was not observed in the corresponding control cells. This result confirmed a previous report that quercetin is a substrate of Bcrp. In the presence of kaempferol, the P app, A-B value of quercetin was greatly increased in MDCK/Bcrp1 cells (2.83 Ϯ 0.65 ϫ 10 Ϫ6 cm/s), compared with that in quercetin alone group (0.232 Ϯ 0.078 ϫ 10 Ϫ6 cm/s). The transport ratio of quercetin in MDCK/Mock cells is 0.85, demonstrating little difference in the A-to-B and B-to-A flux. Compared with that in the quercetin alone group, the transport ratio decreased 11.6-fold (from 97.5 to 8. 
TABLE 1
Transport of quercetin across MDCK cell monolayers transfected with empty vector or Bcrp1
The apparent permeability was calculated as described under Materials and Methods. Table 2 shows the apparent permeability of kaempferol and transport ratios of kaempferol in MDCK cell monolayers. The B-to-A directional transport of kaempferol was much higher than its transport in the A-to-B direction in MDCK/Bcrp1 cells; this phenomenon was not observed in Bcrp1-negative MDCK/Mock cells, suggesting that Bcrp is involved in the transport of kaempferol. In MDCK/Bcrp1 cells, the P app, B-A value of kaempferol was much higher (17.7 Ϯ 3.8 ϫ 10 Ϫ6 cm/s) than the P app, A-B value (0.279 Ϯ 0.037 ϫ 10 Ϫ6 cm/s), with a transport ratio of 63.4. In contrast, the transport ratio of kaempferol was 0.68 in Bcrp1-negative MDCK/Mock cells; however, no statistically significant difference between the P app, A-B value (13.8 Ϯ 6.5 ϫ 10 Ϫ6 cm/s) and P app, B-A value (9.29 Ϯ 0.63 ϫ 10 Ϫ6 cm/s) of kaempferol was observed in MDCK/Mock cells, suggesting no directional flux. Overall, these results indicate that kaempferol is a substrate of Bcrp1.
To further confirm the results of the kaempferol bidirectional transport study, kaempferol uptake, in the absence and presence of the potent Bcrp inhibitor GF120918 (5 M) was examined in MDCK/ Bcrp1 cells. The representative chromatograms of kaempferol (5 M) in the presence or absence of GF120918 in Bcrp1-transfected MDCK cells are shown in Fig. 4B . The peak area of kaempferol increased more than 10-fold when 5 M kaempferol was coincubated with 5 M GF120918. Figure 4C presents the intracellular concentrations of kaempferol when 5, 10, or 15 M kaempferol, with or without GF120918, was incubated with Bcrp1-expressing MDCK/Bcrp1 cells for 1 h. In the presence of GF120918, kaempferol cellular uptake was significantly increased compared with that in the control group at all concentrations tested in current study, indicating that kaempferol is a substrate of Bcrp.
When MDCK/Bcrp1 cells were incubated with different concentrations of kaempferol, we observed that the cellular accumulation of kaempferol was not proportional to its incubation concentration. In the presence of 5 M GF120918, the intracellular amount of kaempferol increased 14.8-fold at 5 M, 2.11-fold at 10 M, and 1.49-fold at 15 M (Table 3) . Because the final cellular concentration of kaempferol is dependent on both passive diffusion and active efflux by Bcrp1, the efflux of kaempferol was calculated as described under Materials and Methods, and the results are given in Table 3 . The estimated K m and E max of kaempferol to Bcrp1 were 1.26 M and 1.89 mol/mg protein, respectively (Fig. 5) .
Kaempferol Transport by MRP2 and P-gp. In addition to Bcrp1, we also examined the role of MRP2 in the transport of kaempferol in MDCK/MRP2 cells. As shown in Fig. 3C , the transport of kaempferol in MDCK/MRP2 cells was similar to that in MDCK/Mock cells, suggesting that kaempferol is not a MRP2 substrate. The P app, A-B value of kaempferol was 18.9 Ϯ 4.2 ϫ 10 Ϫ6 cm/s and the P app, B-A value was 11.6 Ϯ 4.0 ϫ 10 Ϫ6 cm/s in MDCK/MRP2 cells, with a transport ratio of 0.61.
Because P-gp is similar to BCRP in that it has a broad substrate spectrum and plays an important role in the disposition of various compounds, we examined the role of P-gp in the transport of kaempferol (10 M) in P-gp-overexpressing MCF-7/ADR cells and P-gpnegative MCF-7/Sensitive cells. It has been reported that only P-gp, but not BCRP or MRP2, was detected in MCF-7/ADR cells (Zhang et al., 2004) . As is shown in Fig. 6 , the intracellular concentration of kaempferol was greatly increased (ϳ3.2-fold) in the presence of P-gp inhibitor in MCF-7/ADR cells, whereas this phenomenon was not observed in the corresponding P-gp-negative control cells. This result suggested that kaempferol is also a substrate of P-gp. 
Discussion
Although herb-herb interactions between flavonoids have not been extensively investigated, such interactions may explain why individual flavonoids in many cases exhibit greater bioavailability or pharmacological effects when administered as a mixed extract or product rather than in a pure form. Increased bioavailability of individual flavonoids was observed in several studies when a flavonoid was administered with other flavonoids. For example, when Chen et al. (1997) investigated the pharmacokinetics of tea polyphenols in rats, they coincidentally found that epigallocatechin-3-gallate (EGCG) displayed a different pharmacokinetic behavior when it was given in decaffeinated green tea (DGT), compared with pure EGCG. Their results revealed that the absorption rate constant (k a ) increased 3.6-fold for EGCG in DGT than for EGCG administered alone. A lower clearance and higher area under the curve were also observed for EGCG when it was administered as a combination. Moon and Morris (2007) investigated the effect of quercetin and EGCG on the disposition of biochanin A in rats. They found that the area under the curve of biochanin A, after both intravenous and oral administration, increased significantly when it was coadministered with quercetin and EGCG. For these previously reported herb-herb interactions, competitive inhibition of UDP-glucuronosyltransferases and sulfotransferases, the main metabolic pathways for these flavonoids, was proposed as the possible mechanism. In the current study, we investigated the effect of kaempferol on the transport of quercetin in Bcrpoverexpressing cells, and our results clearly showed that there is an interaction between kaempferol and quercetin involving the efflux transporter Bcrp.
In the quercetin bidirectional transport study, we found that in MDCK/Bcrp1 cells the P app, A-B value of quercetin was greatly increased in the presence of kaempferol compared with that in quercetin alone group (2.83 Ϯ 0.65 ϫ 10 Ϫ6 and 0.232 Ϯ 0.078 ϫ 10 Ϫ6 cm/s, respectively). Because A-to-B directional transport is physiologically more relevant to drug absorption, on the basis of our results we would expect an increase in quercetin bioavailability when it is coadministered with kaempferol. It should be noted that although the P app, A-B value of quercetin in MDCK/Bcrp1 increased more than 10-fold in the presence of kaempferol, it is still much lower than the P app, the in vitro observation can be extrapolated to the in vivo situation depends on several factors, such as the Bcrp expression level in the intestine and the intestine concentration of kaempferol after oral administration. Because kaempferol and quercetin are similar in structure, we conducted a kaempferol bidirectional transport study in MDCK-II cells to examine whether kaempferol was also a Bcrp1 substrate. Usually a compound is considered to be a substrate of certain efflux transporter(s) if the transport ratio (P app, B-A /P app, A-B ) Ͼ 2 (Balimane et al., 2006) . In our study, the transport ratio of kaempferol in MDCK/Bcrp1 cells is 63.4, and this transport pattern was not observed in parental MDCK/Mock cells, which have a transport ratio of 0.68. Our results strongly indicated that kaempferol is a substrate of Bcrp. The fact that kaempferol is not only a Bcrp inhibitor but also a Bcrp substrate suggests that kaempferol may inhibit Bcrp-mediated quercetin efflux through competitive inhibition. Moreover, kaempferol is known to be poorly absorbed with a bioavailability as low as 2% (Barve et al., 2009) . Our results also suggested that, in addition to first-pass extraction due to metabolism, efflux transporters such as Bcrp may also represent a possible mechanism for the low bioavailability of kaempferol.
The concentration-dependent transport of kaempferol was studied by examining kaempferol uptake study in MDCK/Bcrp1 cells. Consistent with our transport data, our results from the kaempferol uptake study showed that the intracellular concentrations of kaempferol, at all three concentrations tested (i.e., 5, 10, and 15 M), were significantly increased in the presence of the Bcrp inhibitor GF120918 (5 M), indicating the involvement of Bcrp in the transport of kaempferol. Of interest, with different concentrations of kaempferol, we observed a nonlinear intracellular kaempferol accumulation when kaempferol was incubated alone. The accumulation was proportional to concentration (i.e., linear) when kaempferol was coincubated with GF120918. Because the intracellular accumulation of kaempferol is dependent on both passive diffusion and active efflux by Bcrp1, the linear cellular uptake of kaempferol when it was coincubated with GF120918 suggests that Bcrp1-mediated kaempferol efflux was fully reversed by 5 M GF120918. On the basis of the efflux of kaempferol at different incubation concentrations, we predicted that kaempferol is a Bcrp substrate with high affinity (1.26 M) and low capacity (1.89 mol/mg protein).
To understand whether other efflux transporters, such as MRP2 and P-gp, also play a role in the transport of kaempferol, we conducted a kaempferol bidirectional transport study in MRP2-transfected MDCK/ MRP2 cells and a kaempferol uptake study in P-gp-overexpressing MCF-7/ADR cells. Our previous Western blot data showed that only P-gp, but not BCRP and MRP2, is expressed in MCF-7/ADR cells (Zhang et al., 2004) . Therefore, even though GF120918 is not only a P-gp inhibitor but also a BCRP inhibitor, the increase in kaempferol uptake in MCF7/ADR cells in the presence of GF120918 indicates that kaempferol is a P-gp substrate. Although MRP2 is well known to transport organic anions and P-gp usually mediates the efflux of uncharged or cationic hydrophobic compounds, our results showed that kaempferol, an organic anion, is a substrate of P-gp but not MRP2 (Leslie et al., 2005; Choudhuri and Klaassen, 2006 ). Considering the high expression level of P-gp in intestine, P-gp, in addition to Bcrp, may also contribute to the poor absorption of kaempferol after oral consumption.
Endogenous expression of drug transporters in various cell lines has been investigated by Goh et al. (2002) , and their results demonstrated the endogenous MDR1 mRNA expression in MDCK-II cells. The same group also found that canine MDR1 shares 78% amino acid identity with the human MDR1. However, when kaempferol was transported across parental MDCK-II cell monolayers, no directional transport of kaempferol was observed although kaempferol was also found to be a P-gp substrate in our uptake study. This observation might be due to the very low expression of MDR1 in MDCK-II cells, the low affinity of kaempferol to P-gp, or functional differences of P-gp among different species. Therefore, it is not expected that P-gp would contribute to the flux observed in MDCK/Bcrp1 cells.
In conclusion, we report for the first time that kaempferol is a Bcrp substrate with high affinity (K m ϭ 1.26 M) and low capacity (E max ϭ 1.89 mol/mg protein). Kaempferol influenced Bcrp-mediated transport of quercetin, indicating its role as a BCRP inhibitor. Whether kaempferol inhibits Bcrp-mediated quercetin efflux through competitive inhibition requires further investigation. Other than first-pass metabolism, intestinal efflux by the efflux transporters Bcrp and P-gp may also represent one possible mechanism for the poor bioavailability of kaempferol. The use of flavonoids in combination may increase their bioavailability through transport interactions.
